Pyxis secures ADC licence from Pfizer
Massachusetts-based biotechnology start-up Pyxis Oncology has secured a licensing deal with Pfizer for two of the pharmaceutical giant’s antibody-drug conjugates.
Reviewing the inter partes review
The establishment of the US Patent Trial and Appeal Board in 2012 changed the game for patent owners. And while life science patents have not always been under the spotlight, recent trends suggest more such patents are being reviewed than ever before.
Genevant signs $600m liver fibrosis deal with Takeda
Genevant Sciences has entered into a licence agreement for Takeda to develop and market a new liver fibrosis treatment.
Biogen sues Teva over MS generic
A proposed Teva Pharmaceutical generic drug to treat multiple sclerosis infringes patents relating to Vumerity, according to a lawsuit filed by Biogen and Alkermes.
FTC launches pharma merger analysis group
The Federal Trade Commission (FTC) is launching a new international working group in an “imperative” move to better analyse the impact of pharmaceutical mergers.
NCAA targets ‘Vasectomy Mayhem’ trademark
The National Collegiate Athletic Association has filed a petition to cancel a urology centre's ‘Vasectomy Mayhem’ trademark ahead of the NCAA’s March Madness Basketball Tournament.
Medical tech leads 2020 innovation at the EPO
Healthcare innovation led patenting activity in 2020 as COVID-19 fuelled a rise in applications, a report by the European Patent Office has revealed.
Fed Circuit rejects Stanford Uni’s ‘abstract’ genetics patent
Stanford University can’t patent a genetic testing method as it is based on “abstract mathematical calculations”, the US Court of Appeals for the Federal Circuit has ruled.
Pressure on Ireland to back COVID vaccine IP waiver
Ireland is the latest country to come under pressure to back the World Trade Organisation’s appeal to waive intellectual property rights related to COVID-19 vaccines, as developing countries struggle to vaccinate their populace.
Federal Circuit affirms PTAB’s Baxter ruling
The US Court of Appeals for the Federal Circuit has affirmed decisions from the Patent Trial and Appeal Board, knocking out two Baxter patents.
